RT Journal Article SR Electronic T1 â–¼Pantoprazole - a third proton pump inhibitor JF Drug and Therapeutics Bulletin JO Drug Ther Bull FD BMJ Publishing Group Ltd SP 93 OP 94 DO 10.1136/dtb.1997.351293 VO 35 IS 12 YR 1997 UL http://dtb.bmj.com/content/35/12/93.abstract AB Relevant BNF section: 1.3.5Pantoprazole (Protium - Knoll) is the third proton pump inhibitor to be marketed in the UK. It is licensed for the treatment of duodenal ulcer, benign gastric ulcer and reflux oesophagitis. Unlike omeprazole and lansoprazole, pantoprazole is not licensed for maintenance therapy in these disorders nor for use in the treatment of Helicobacter pylori infection. The manufacturer claims that pantoprazole offers "precise control in acid-related disorders", with "selective targeting" of the proton pump, "predictable pharmacokinetics" and minimal risk of interactions with other drugs. Does pantoprazole offer any advantage over established proton pump inhibitors?